(Q40513410)

21 September 2017

1 reference

title

Venlafaxine. A review of its pharmacology and therapeutic potential in depression (English)

1 reference

21 September 2017

1 reference

S M Holliday

1

1 reference

21 September 2017

P Benfield

series ordinal

2

1 reference

21 September 2017

publication date

1 February 1995

1 reference

21 September 2017

1 reference

21 September 2017

volume

49

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

280-294

1 reference

An open-label, variable-dose study of WY-45,030 (venlafexine) in depressed outpatients

21 September 2017

cites work

1 reference

12 December 2020

Pharmacodynamics of venlafaxine evaluated by EEG brain mapping, psychometry and psychophysiology

1 reference

12 December 2020

The epidemiology of depression in medical care

1 reference

12 December 2020

Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative

1 reference

12 December 2020

Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression

1 reference

12 December 2020

Clinical experience with serotonin reuptake inhibiting antidepressants

1 reference

12 December 2020

DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity

1 reference

12 December 2020

Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study

1 reference

12 December 2020

A comparison of venlafaxine, trazodone, and placebo in major depression.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol

1 reference

12 December 2020

Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations

1 reference

12 December 2020

Acute effects of the novel antidepressant venlafaxine on cognitive event-related potentials (P300), eye blink rate and mood in young healthy subjects.

1 reference

12 December 2020

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

12 December 2020

Venlafaxine in depressed outpatients

1 reference

12 December 2020

Inhibition by fluoxetine of cytochrome P450 2D6 activity.

1 reference

12 December 2020

Adverse effects of antidepressants in the elderly

1 reference

12 December 2020

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression

1 reference

12 December 2020

The changing rate of major depression. Cross-national comparisons. Cross-National Collaborative Group

1 reference

12 December 2020

Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder

1 reference

12 December 2020

Venlafaxine for treatment-resistant unipolar depression

1 reference

12 December 2020

Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes

1 reference

12 December 2020

A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group

1 reference

12 December 2020

NIH consensus conference. Diagnosis and treatment of depression in late life

1 reference

12 December 2020

The effect of renal disease on the disposition of venlafaxine

1 reference

12 December 2020

Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients

1 reference

12 December 2020

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics

1 reference

12 December 2020

Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors

1 reference

12 December 2020

Placebo-controlled trial of venlafaxine for the treatment of major depression

1 reference

12 December 2020

The disposition of venlafaxine enantiomers in dogs, rats, and humans receiving venlafaxine

1 reference

12 December 2020

Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring

1 reference

12 December 2020

Venlafaxine exhibits pre-clinical antidepressant activity in the resident-intruder social interaction paradigm.

1 reference

12 December 2020

An open-label, dose-finding study of WY-45,030, a novel bicyclic antidepressant.

1 reference

12 December 2020

Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man

1 reference

12 December 2020

10.2165/00003495-199549020-00010

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

1026551274

0 references

1 reference